Marker Therapeutics awarded $2.6 million FDA grant for pancreatic cancer program
The FDA awarded Marker Therapeutics a $2.6 million Orphan Products Development grant to advance MT-601 in pancreatic cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.